The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: A retrospective cohort study

Breast Cancer Research

Volumn 14, Issue 6, 2012, Pages

  Rhiem, Kerstin ^a   Engel, Christoph ^b   Graeser, Monika ^a   Zachariae, Silke ^b   Kast, Karin ^c   Kiechle, Marion ^d   Ditsch, Nina ^e   Janni, Wolfgang ^f   Mundhenke, Christoph ^g   Golatta, Michael ^h   Varga, Dominic ⁱ   Preisler Adams, Sabine ^j   Heinrich, Tilman ^k   Bick, Ulrich ^l   Gadzicki, Dorothea ^m   Briest, Susanne ⁿ   Meindl, Alfons ^d   Schmutzler, Rita K ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ UNIVERSITY HOSPITAL ULM   (Germany)

^j UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^k UNIVERSITY OF WÜRZBURG   (Germany)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m HANNOVER MEDICAL SCHOOL   (Germany)

ⁿ UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CALCULATION; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; AGE; BREAST; BREAST NEOPLASMS; CLINICAL TRIAL; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETICS; MULTICENTER STUDY; PATHOLOGY; RISK;

AGE FACTORS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RETROSPECTIVE STUDIES; RISK;

EID: 84870526600     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3369     Document Type: Article

References (26)

1. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck RT, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689. 10.1086/301749, 1376944, 9497246.
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Gene 2003, 72:1117-1130.
3. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006, 24:2437-2443. 10.1200/JCO.2005.02.7888, 16636335.
4. Pierce LJ, Haffty BG. Radiotherapy in the treatment of hereditary breast cancer. Semin Radiat Oncol 2011, 21:43-50. 10.1016/j.semradonc.2010.08.008, 21134653.
5. Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation Carriers. J Clin Oncol 2009, 27:5887-5892. 10.1200/JCO.2008.19.9430, 19858402.
6. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004, 6:R8-R17. 10.1186/bcr658, 314444, 14680495.
7. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H, . Hereditary Breast Cancer Clinical Study Group Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000, 356:1876-1881. 10.1016/S0140-6736(00)03258-X, 11130383, Hereditary Breast Cancer Clinical Study Group.
8. Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, Haffty BG, Ben-David M, Kaufman B, Garber JE, Merajver SD, Balmaña J, Meirovitz A, Domchek SM. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010, 121:389-398. 10.1007/s10549-010-0894-z, 2936479, 20411323.
9. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004, 22:2328-2335. 10.1200/JCO.2004.04.033, 15197194.
10. Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2011, 104:1384-1392. 10.1038/bjc.2011.120, 3101934, 21487411.
11. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA. Hereditary Breast Cancer Clinical Study Group: tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: an update. Int J Cancer 2006, 118:2281-2284. 10.1002/ijc.21536, 16331614.
12. Tilanus-Linthorst MM, Alves C, Seynaeve C, Menke-Pluymers MB, Eggermont AM, Brekelmans CT. Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer. Br J Surg 2006, 93:961-968. 10.1002/bjs.5344, 16758466.
13. Tilanus-Linthorst MM, Bartels KC, Alves C, Bakri B, Crepin E, van den Ouweland A, Klijn JG, Meijers-Heijboer H, Brekelmans CT. Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients. Breast Cancer Res Treat 2006, 95:117-123. 10.1007/s10549-005-9054-2, 16319990.
14. King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M, Morrow M. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 2011, 29:2158-2164. 10.1200/JCO.2010.29.4041, 21464413.
15. Khan SA. Contralateral prophylactic mastectomy: What do we know and what do our patients know?. J Clin Oncol 2011, 29:2132-2135. 10.1200/JCO.2010.33.4482, 21464412.
16. Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 2011, 108:323-330. 3106175, 21637635.
17. Meindl A, . German Consortium for Hereditary Breast and Ovarian Cancer Comprehensive analysis of 989 patients with breast and ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002, 97:472-480. German Consortium for Hereditary Breast and Ovarian Cancer.
18. Nichols H, Berrington de Gonzalez A, Lacey JV, Rosenberg PS, Anderson WF. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 2011, 29:1564-1569. 10.1200/JCO.2010.32.7395, 3082975, 21402610.
19. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 2009, 101:1058-1065. 10.1093/jnci/djp181, 2720990, 19590058.
20. Brewster AM, Parker PA. Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist 2011, 16:935-941. 10.1634/theoncologist.2011-0022, 3228146, 21672945.
21. Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Lüchtenborg M. Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast Cancer Res Treat 2011, 130:609-618. 10.1007/s10549-011-1618-8, 21671018.
22. Vichapat V, Gillett C, Fentiman IS, Tutt A, Holmberg L, Lüchtenborg M. Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. Eur J Cancer 2011, 47:1919-1927. 10.1016/j.ejca.2011.05.004, 21658939.
23. Boughey JC, Hoskin TL, Degnim AC, Sellers TA, Johnson JL, Kasner MJ, Hartmann LC, Frost MH. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 2010, 17:2702-2709. 10.1245/s10434-010-1136-7, 20853163.
24. Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Boice JD, Anton-Culver H, Bernstein JL. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 2010, 28:2404-2410. 10.1200/JCO.2009.24.2495, 2881721, 20368571.
25. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304:967-975. 10.1001/jama.2010.1237, 2948529, 20810374.
26. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 2003, 21:1675-1681. 10.1200/JCO.2003.09.052, 12721241.